Abalytics Oncology
Abalytics Oncology is a biotechnology company focused on redefining cancer drug development through computational antibody design and biomolecular engineering. Their core values emphasize improving overall survival, quality of life, and gaining greater understanding in cancer treatment. The company's strategic mission for 2025 and beyond includes developing best-in-class CTLA-4 targeting bispecific antibodies, next-generation multispecific therapies, and building data models to address immune dysregulation. They leverage their proprietary Abalytics Intelligence platform, which utilizes artificial intelligence and algorithms for target selection, antibody design, and translational modeling. Their pipeline includes bispecific oncology therapies like ABAO3 (PD-1/CTLA-4) and ABAO6 (pMHC/CD3), aiming to enhance safety and efficacy while minimizing toxicity. The company's approach focuses on creating modular, next-generation antibody formats for optimized safety and efficacy in cancer treatment.
Abalytics Oncology
Abalytics Oncology is a biotechnology company focused on redefining cancer drug development through computational antibody design and biomolecular engineering. Their core values emphasize improving overall survival, quality of life, and gaining greater understanding in cancer treatment. The company's strategic mission for 2025 and beyond includes developing best-in-class CTLA-4 targeting bispecific antibodies, next-generation multispecific therapies, and building data models to address immune dysregulation. They leverage their proprietary Abalytics Intelligence platform, which utilizes artificial intelligence and algorithms for target selection, antibody design, and translational modeling. Their pipeline includes bispecific oncology therapies like ABAO3 (PD-1/CTLA-4) and ABAO6 (pMHC/CD3), aiming to enhance safety and efficacy while minimizing toxicity. The company's approach focuses on creating modular, next-generation antibody formats for optimized safety and efficacy in cancer treatment.